You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NEWS / CORPORATE / .........

CORPORATE - 16-04-2014

Kedrion Group approves 2013 financial statements

A 425 million euros turnover with a 12% rise on 2012; global sales accounting for 66% of the overall turnover; a 25% EBITDA, 4 points more than in the previous financial year; a net profit of 34 million euros. Here are the key figures of Kedrion’s financial statements, approved on 15th April by the shareholders’ meeting.
In 2013 also the company continued its trend of expansion on global markets, mostly in the United States where it exceeded 135 million euros.

For more information please contact: